Study of drug AZD4144 in people with liver problems
This study tests how a new drug (AZD4144) is processed by the body in people with different levels of liver function. It aims to see if the drug is safe and how the liver affects its levels, which may help guide future dosing for patients with liver problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a stable liver condition that has lasted at least 6 months (this is called 'hepatic impairment').
- You must be classified as Child-Pugh Class A, B, or C — your doctor can tell you which class you are.
- You must be on a stable medication regimen (no new medicines or dose changes for at least 2 weeks before starting).
- You must weigh at least 50 kg (about 110 lbs) and have a BMI between 18 and 45.
- You must not have Type 1 or Type 2 diabetes (if you are a healthy volunteer), a history of certain heart rhythm problems, or a weakened immune system.
- You must not be taking immunosuppressive drugs, steroids, or have had certain vaccines within the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This study tests how a new medicine, BI 3000202, is absorbed into the blood. It includes people with different levels of liver function (normal, mild, moderate, or severe) to see if liver problems affect how the medicine works.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This trial tests a new medicine in healthy men to see how the body absorbs, breaks down, and removes it. This helps doctors understand how the drug works, which may lead to better treatments in the future.
This is an early-stage study testing a new medicine called PF-08653944 in healthy adults and in people with varying degrees of liver function problems. The goal is to understand how the medicine works in the body and how liver function affects how the body processes it.
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.